AMI患者治疗前后血清IGF-Ⅱ和血浆ET检测的临床意义

Clinical Significance of Measurement of Changes of Serum IGF-Ⅱ and Plasma ET Contents After Treatment in Patients with Acute Myocardial Infarction(AMI)

目的:探讨了急性心肌梗死(AMI)患者治疗前后血清IGF-Ⅱ和血浆ET水平的变化。方法:应用放免法测定了36例AMI患者治疗前后血清IGF-Ⅱ和血浆ET含量,并与30例正常健康人作比较。结果:AMI患者在治疗前血清IGF-Ⅱ和血浆ET水平非常显著地高于正常对照组(P<0.01),并且呈显著正相关(r=0.6128,P<0.01)。经一个月治疗后血清IGF-Ⅱ水平与正常人比较无显著性差异(P>0.05),但血浆ET水平与正常人比较仍有显著差异(P<0.05)。结论:检测AMI患者血清IGF-Ⅱ和血浆ET水平的变化对临床观察预后有重要的临床价值。

Objective To explore the clinical significance of changes of serum IGF - Ⅱ and plasma ET levels in patients with AMI after treatment. Methods Serum IGF - Ⅱ and plasma ET levels were measured with RIA in 36 patients with acute myocardial infarction both before and after treatment as well as in 30 controls. Results Serum IGF - Ⅱ and plasma ET levels were significantly higher in the AMI patients than those in the controls before treatment and the levels were mutually positively correlated （P 〈 0.01 ）. One month after treatment, the serum IGF - Ⅱ level in the patients were not much different from those in the controls（P 〉0.05）, but plasma ET levels remained significantly higher （P 〈 0.05 ）. Conclusion Changes of serum IGF - Ⅱ and plasma ET levels after treatment might be of prognostic importance in patients with acute myocardial infarction.